Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi neuropsykiatrisien häiriöiden hoitoon
February 14, 2022 02:00 ET
|
Nexstim Oyj
Yhtiötiedote, sisäpiiritieto, Helsinki, 14.2.2022 klo 9.00 (EET) Nexstim Oyj lisensoi kehittämäänsä teknologiaa yhdysvaltalaiselle lääkintäteknologiayhtiö Magnus Medical, Inc.:ille käytettäväksi...
Nexstim har kommit överens om en strategisk investering i en Management Services-organisation för en Kalifornien-baserad klinik som tillhandahåller behandlingar för depressionspatienter
November 22, 2021 02:00 ET
|
Nexstim Oyj
Företagsmeddelande, insiderinformation, Helsingfors, 22.11.2021 kl. 9.00 (EET) Nexstim har kommit överens om en strategisk investering i en Management Services-organisation för en Kalifornien-baserad...
Nexstim on sopinut strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön
November 22, 2021 02:00 ET
|
Nexstim Oyj
Yhtiötiedote, sisäpiiritieto, Helsinki, 22.11.2021 klo 9.00 (EET) Nexstim on sopinut strategisesta investoinnista masennuspotilaille hoitoja tarjoavaan kalifornialaisen klinikan palveluyhtiöön ...
Nexstim Agrees on a Strategic Investment into a Management Services Organisation of a California Based Clinic Providing Treatments for Depression Patients
November 22, 2021 02:00 ET
|
Nexstim Oyj
Company Announcement, Inside information, Helsinki, 22.11.2021 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organisation of a California Based Clinic Providing...
Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
August 23, 2021 06:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
December 01, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months Rapid and substantial improvement in...
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
November 04, 2020 07:03 ET
|
Axsome Therapeutics, Inc.
Collaboration provides Axsome access to new digital technologies developed by Veeva NEW YORK and PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder
September 14, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001) Clinical...
Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program
August 10, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Enrollment complete in the COMET Phase 3 long-term safety trial of AXS-05 in MDD; NDA filing on track for 4Q 2020 Results from three Phase 2 open-label efficacy trials of AXS-05 in TRD,...
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder
July 13, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NDA submission on track for 4Q 2020 NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...